Browsing Barts Cancer Institute by Subject "5.1 Pharmaceuticals"
Now showing items 1-4 of 4
-
Abstract 958: Effective targeting of pancreatic ductal adenocarcinoma metastases with an integrin αvβ6-targeting peptide-drug conjugate
(American Association for Cancer Research (AACR), 2021-07-01) -
Abstract P6-10-05: Mutations in the RNA Splicing Factor SF3B1 drive endocrine therapy resistance and confer a targetable replication stress response defect through PARP inhibition
(American Association for Cancer Research (AACR), 2023-03-01) -
Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.
(American Society of Clinical Oncology (ASCO), 2024-05-29)